Mayo Clinic Arizona, Phoenix, AZ, United States.
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, United States.
Transpl Int. 2023 Sep 27;36:11455. doi: 10.3389/ti.2023.11455. eCollection 2023.
Kidney transplantation offers better mortality and quality of life outcomes to patients with end-stage renal failure compared to dialysis. Specifically, living donor kidney transplantation is the best treatment for end-stage renal disease, since it offers the greatest survival benefit compared to deceased donor kidney transplant or dialysis. However, not all patients from all racial/ethnic backgrounds enjoy these benefits. While black and Hispanic patients bear the predominant disease burden within the United States, they represent less than half of all kidney transplants in the country. Other factors such as cultural barriers that proliferate myths about transplant, financial costs that impede altruistic donation, and even biological predispositions create a complex maze and can also perpetuate care inaccessibility. Therefore, blanket efforts to increase the overall donation pool may not extend access to vulnerable populations, who may require more targeted attention and interventions. This review uses US kidney transplantation data to substantiate accessibility differences amongst racial minorities as well as provides examples of successful institutional and national systemic level changes that have improved transplantation outcomes for all.
与透析相比,肾移植可为终末期肾衰竭患者提供更好的死亡率和生活质量结果。具体来说,活体供肾移植是治疗终末期肾病的最佳方法,因为与已故供体肾移植或透析相比,它提供了最大的生存获益。然而,并非所有来自不同种族/族裔背景的患者都能从中受益。虽然黑人和西班牙裔患者在美国承担着主要的疾病负担,但他们在全国的肾移植中不到一半。其他因素,如传播有关移植的误解的文化障碍、阻碍利他主义捐赠的经济成本,甚至是生物倾向,都会造成一个复杂的迷宫,也可能使护理无法获得。因此,增加整体捐赠群体的全面努力可能并不能为弱势群体提供更多机会,他们可能需要更多的针对性关注和干预。本综述使用美国肾移植数据来证实少数族裔之间的可及性差异,并提供了一些成功的机构和国家系统层面的变革的例子,这些变革改善了所有人的移植结果。